vrdct.Open terminal

Trade the next
biotech catalyst.

An onchain market for defined drug outcomes. Trade USDC-backed YES/NO tokens, or fund liquidity through VLP.

Explore marketsMeet VLP

Research and virtual trading available. Real transactions disabled.

One event.
Two sides.

Isolate a defined approval event from whole-company exposure. Each USDC backs one YES and one NO together, issued as standard ERC20 claims. Final payouts follow the committed rules.

Resolve as
100 YES claims cost$62
Final payout$100
Illustrative P&L+$38

Teaching example, not a quote or forecast. Fees and execution excluded. INVALID pays 50¢ per claim.

Know what’s
behind the claim.

Drug, indication, trial and primary evidence. A real research example:

Lonvo-z Intellia Therapeutics · hereditary angioedema

FDA approval candidate. Sponsor target: Mar 10, 2027. A research snapshot, not a listed market or trading cutoff.

Drug profileCompanyHAELO trialPubMed publication

Capital that makes
a market possible.

Explore VLP

Traders can fund new positions together. VLP adds bounded AMM liquidity through a closed USDC cohort. Holders earn allocated fees and bear inventory risk.

One cohort.One flagship event.Defined exposure limits.

Start with a view.
Follow the evidence.

Explore the research

Event claims give no company equity or drug IP. Prices are not clinical forecasts. Trading and liquidity provision can lose capital; costs, basis risk and disputes matter. Understand the risks